Tag: Nateglinide

According to the CDC, approximately 1 in 10 Americans has diabetes, and many require medication to manage their blood sugar levels. Among these, meglitinides are a unique class of drugs used for type 2 diabetes. The action of the meglitinides involves stimulating a rapid, short-lived burst of insulin from the pancreas to manage post-meal glucose spikes.

In some studies, post-prandial hyperglycemia (high blood sugar after meals) was recorded at least once in 84% of patients with otherwise well-controlled type 2 diabetes. For these individuals, knowing **when should meglitinides be administered** is critical for managing these glucose spikes.

With diabetes affecting millions worldwide, the cost of medications is a critical concern [1.5.1]. The price of nateglinide active pharmaceutical ingredient (API), a key component for treating type 2 diabetes, is influenced by numerous market factors [1.3.5, 1.4.2]. So, what is the price of nateglinide API and what drives its cost?

In clinical trials, an upper respiratory tract infection was reported in over 10% of patients taking Starlix, making it one of the most common findings for those wondering which is a side effect of Starlix. This medication, also known by its generic name nateglinide, is a prescription oral drug used to help manage type 2 diabetes by stimulating rapid insulin release after meals. However, like all medications, it comes with a range of potential side effects, from common inconveniences to more serious complications. A comprehensive understanding of these risks is crucial for patient safety and effective treatment.

In 2023, the brand-name diabetes medication Starlix (nateglinide) was officially discontinued in the U.S., following a similar withdrawal from the European market years prior. The definitive reason why was Starlix discontinued, according to its manufacturer, was based on commercial viability and diminishing market demand, not safety issues.

Nateglinide is a medication that begins stimulating insulin release within 20 minutes of a dose and has a blood-sugar-lowering effect that lasts for approximately 4 hours. This rapid onset and short duration is precisely how nateglinide works to manage postprandial glucose levels in adults with Type 2 diabetes.

Nateglinide stimulates pancreatic insulin secretion within 20 minutes of oral administration, offering a rapid but short-lived effect. As a meglitinide medication for managing type 2 diabetes, its distinct pharmacokinetic profile directly influences its clinical use, but the central question remains: **how long does nateglinide last**? The answer is crucial for understanding its role in controlling postprandial glucose levels.

In clinical trials, non-severe hypoglycemia occurred in 2.4% of patients treated with nateglinide, a key consideration for its use [1.3.8]. Understanding What are the disadvantages of nateglinide? is crucial for managing type 2 diabetes safely and effectively.

According to a 2002 study published in *Diabetes Care*, nateglinide was found to be effective and safe in reducing postprandial hyperglycemia in subjects with impaired glucose tolerance. In general, what are the benefits of nateglinide for individuals with type 2 diabetes?

Clinical trial data from the FDA reveals that patients taking Starlix (nateglinide) experienced statistically significant mean weight increases compared to those on placebo. This raises a common question for many individuals managing type 2 diabetes: **Does Starlix cause weight gain?**